As of November 6, 2026, IDEAYA Biosciences, Inc. is a publicly traded company (Nasdaq: IDYA); its largest reported holder is Janus Henderson, with 8.3% on Schedule 13G/A of May 15, 2026, then Capital Research Global Investors (6%). The largest insider holding is Yujiro S. Hata, the chief executive and president, with 690,695 shares (0.71% of shares outstanding), per Form 4 of October 8, 2026 (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in IDEAYA Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is IDEAYA Biosciences, Inc. a real, registered company?
- IDEAYA Biosciences, Inc. files with the SEC under CIK 1676725 (its SEC filings).
- Its shares are listed under the ticker IDYA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under IDEAYA Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Baker Bros. Advisors LP (filed 2026-08-14).
Who are IDEAYA Biosciences, Inc.'s owners and officers?
IDEAYA Biosciences, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Baker Bros. Advisors LP | 5.2% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.08% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 8.3% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Point72 Asset Management, L.P. | 2.1% |
| Schedule 13G/A, 2026-02-12 | Capital Research Global Investors | 6% |
| Schedule 13G/A, 2026-01-08 | Federated Hermes, Inc. | 3.87% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 7.3% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 6.9% |
| Schedule 13G, 2025-08-13 | Capital Research Global Investors | 7.5% |
Questions about who owns IDEAYA Biosciences, Inc.
Who owns IDEAYA Biosciences, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of IDEAYA Biosciences, Inc.: Janus Henderson Group PLC (8.3%, Schedule 13G/A, filed 2026-05-15), Capital Research Global Investors (6%, Schedule 13G/A, filed 2026-02-12), Baker Bros. Advisors LP (5.2%, Schedule 13G, filed 2026-08-14) and Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of IDEAYA Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of IDEAYA Biosciences, Inc. on this page are Janus Henderson Group PLC (8.3%), Capital Research Global Investors (6%) and Baker Bros. Advisors LP (5.2%).
When did Janus Henderson Group PLC buy into IDEAYA Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 6.9%; its latest, Schedule 13G/A filed 2026-05-15, reports 8.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on IDEAYA Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on IDEAYA Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IDEAYA Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own IDEAYA Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 690,695 shares (0.71% of shares outstanding) (Form 4, 2026-10-08).
- , a director: 57,644 shares (0.06% of shares outstanding), 54,281 held directly and 3,363 indirectly (Form 4, 2026-03-02).
- , the chief accounting officer: 26,466 shares (0.03% of shares outstanding) (Form 4, 2026-07-09).
- , the general counsel and senior vice president: 2,080 shares (0.00% of shares outstanding) (Form 4, 2026-02-02).
Shares outstanding: 96,694,575 as of 2026-10-31, from the company's latest SEC cover page.
How much has IDEAYA Biosciences, Inc. raised?
No fundraising or offering filing from IDEAYA Biosciences, Inc. is on file with us.
Keep reading
More on IDEAYA Biosciences, Inc. and the records around it.
IDEAYA Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ideaya-biosciences